CanSino Biologics, Inc. Class A
3.23
EUR
-0.22
(-6.43%)
ISIN
CNE100003F01
Return %
Stock
S&P 500
1Y
-32.47
14.20
3Y
15.29
81.12
5Y
-86.85
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Xue Feng Yu
- Full Time Employees
- 1,134
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 401-420, Biomedical Park Tianjin TI China 300457
- IPO Date
- Mar 28, 2019
- Website
- cansinotech.com
- Similar Companies
- Business
- CanSino Biologics Inc. (688185.SS) develops, manufactures and commercializes innovative vaccines targeting infectious diseases; its launched products include Menhycia (Group ACYW135 meningococcal polysaccharide conjugate vaccine CRM197), iPneucia (13-valent pneumococcal polysaccharide conjugate vaccine CRM197/TT PCV13i), Menphecia (Groups A and C meningococcal polysaccharide conjugate vaccine CRM197), Convidecia (recombinant novel coronavirus vaccine adenovirus type 5 vector), Convidecia Air (recombinant novel coronavirus vaccine adenovirus type 5 vector for inhalation) and Ad5-EBOV (recombinant Ebola virus vaccine); the company leverages five key platform technologies comprising adenovirus-based viral vector technology, synthetic biotechnology, protein structure design and VLP assembly, mRNA and LNP technology, and formulation and drug delivery technology. Founded in 2009 and headquartered in Tianjin China, CanSino Biologics operates large-scale manufacturing bases in Tianjin and Shanghai, with fill-and-finish production lines in Mexico, Pakistan and Malaysia; it maintains a marketing and supply system spanning Asia, Latin America, Africa and other regions, while advancing a pipeline covering more than 10 diseases such as pneumonia, pertussis, diphtheria, tetanus, tuberculosis and shingles. Recent developments encompass the September 2025 domestic launch of iPneucia and international shipment of Menhycia, a US$17 million grant from the Bill & Melinda Gates Foundation in October 2024 to advance its recombinant poliovirus vaccine (VLP-Polio) project and related combination vaccines, a licensing agreement with PanRu Biotech in November 2025 to expand three-component LNP delivery system applications, the initiation of a Phase I clinical trial for its inhaled tuberculosis vaccine in Indonesia in November 2025, and a strategic collaboration on mRNA multi-valent influenza vaccines announced in its 2025 interim results; the company also submitted Menhycia for expanded age indication approval to 3 months to 6 years and continues Phase I trials for its recombinant shingles vaccine.
Company News
CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines
CanSino Biologics CEO on earnings, business outlook, and international partnerships
Riding Covid Vaccine Highs, CanSino Plans Swiss Listing
Why Is CanSino Biologics (CASBF) Stock Soaring Today?
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
COVID shot drives CanSinoBIO's first six-month profit since at least 2019
Pandemic Accelerates China's Drive Into mRNA Treatments